

MELANOMA BRIDGE

1-3 dicembre 2026

Napoli, Royal Continental Hotel (Via Partenope 38)

Responsabile Scientifico

Paolo A. Ascierto | Professore Ordinario di Oncologia, Università Federico II, Napoli; Direttore Struttura Complessa Oncologia Sperimentale, Melanoma, Immunoterapia e Terapie Innovative, Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale, Napoli

Congresso ECM

Destinatari dell'attività formativa:

Farmacista (Farmacista pubblico del SSN); **Medico Chirurgo** (Allergologia ed immunologia clinica; dermatologia e venereologia; ematologia; gastroenterologia; Malattie dell'apparato respiratorio; medicina interna; nefrologia; neurologia; oncologia; radioterapia; chirurgia generale; chirurgia plastica e ricostruttiva; ginecologia e ostetricia; urologia; anatomia patologica; farmacologia e tossicologia clinica; laboratorio di genetica medica; medicina nucleare; patologia clinica (laboratorio di analisi chimico-cliniche e microbiologia); radiodiagnostica; igiene, epidemiologia e sanità pubblica; medicina generale (medici di famiglia); Scienza dell'alimentazione e dietetica; cure palliative);

Quota di iscrizione: 880,00 euro è IVA 22% (include partecipazione ai lavori congressuali, breaks come da programma, congress bags)

Quota di iscrizione ridotta SOCI AIOM: 600,00 euro + IVA 22%

n. 5 iscrizioni gratuite SOCI AIOM

RAZIONALE SCIENTIFICO

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune and target therapies has further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities.

This year latest findings in melanoma research and advances on topics of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the dedicated sessions, focused

on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

PROGRAMMA SCIENTIFICO

**Speakers to be confirmed*

*** not CME accreditation*

DAY 1

Tuesday, Dec 1st

OPENING CEREMONY

Chairpersons: *Paolo A. Ascierto, Franco Marincola**

6.00 PM Update in Neoadjuvant research, *Elizabeth M. Burton*

6.20 PM Update in Pathology, *Carlo Bifulco**

6.40 PM Next Breakthrough Therapies in Uveal Melanoma, and Clinical Challenges
Kevin O'Neill and Marlana Orloff

7.10 PM MRA Funding Opportunities and Initiatives to Accelerate Research for Cutaneous and
Rare Melanoma Subtypes, *Joan Levy*

7.20 PM Patient Advocacy, *Samantha Guild and Claudia Piazza Cidonio*

DAY 2

Wednesday, Dec 2nd

9.15 AM Introduction and objectives, *Paolo A. Ascierto*

SESSION 1 - MORE TRANSLATIONAL RESEARCH IN MELANOMA

Chairpersons: *Giuseppe Masucci*, Christian Blank**

9.20 AM Translational data from personalized cancer vaccination trials, *Ryan Sullivan*

9.35 AM Metabolism, *Alpaslan Tasdogan**

9.50 AM Harnessing CD26hi T cells to mediate potent activity against melanoma, *Chrystal M. Paulos*

10.05 AM TBD, *Jennifer Guerriero**

10.20 AM TME, *Charles Swanton**

10.35 AM Spatial Trans-Criptomics, *Florian Rambow**

10.50 AM Genomic approaches, *Tomas Kirchhoff**

11.05 AM Discussion

11.30 AM Coffee Break**

11.45 AM SYMPOSIUM

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

12.35 PM Prediction of therapy outcome: Biological markers VS AI predictive algorithm, *Christian Blank** VS *Georgina Long**

1.00 PM Use of ctDNA monitoring to guide clinical decisions, ready for primetime now: YES or NO
*Reinhard Dummer VS Dirk Schadendorf**

1.25 PM Lunch**

SESSION 2 – WHAT HAVE WE LEARNED FROM...

Chairpersons: Igor Puzanov, Corrado Caracò

2.15 PM ...failed studies? *Jeffrey Sosman**

2.30 PM ...studies ongoing that haven't read out? *Olivier Michielin**

2.45 PM ...clinical gaps in Melanoma? *Omid Hamid*

3.00 PM What are we learning with PD-L1/IDO vaccination? *James Smithy*

3.15 PM ...using a common control arm: opportunities and challenges, *Ryan Sullivan*

3.30 PM DISCUSSION

3.50 PM SYMPOSIUM Target Therapy in Metastatic Melanoma

Chairperson: Paolo A. Ascierto

*Paolo A. Ascierto, Reinhard Dummer**

4.40 PM SYMPOSIUM Bridging evidence and experience in Metastatic Uveal Melanoma

Chairperson: Paolo A. Ascierto

Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial, *Paul Nathan**

Translating evidence into practice: international experience with tebentafusp in metastatic uveal melanoma, *Ester Simeone**

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori

5.20 PM TIL: frontline vs second line, *Allison Betof Warner vs Igor Puzanov*

5.45 PM Reality Check of Benefits: all Stages vs Advanced Stages, *Alexander Eggermont vs Michael Postow*

DAY 3

Thursday, December 3rd

SESSION 3 - EMERGENT STRATEGIES

Chairpersons: *Giuseppe Palmieri**, *Iman Osman*

9.00 AM Brain Metastases, *Hussein Tawbi*

9.15 AM Acral Melanoma, *Mitch Levesque**

9.30 AM Mucosal Melanoma, *Alex Shoushtari**

9.45 AM Neoadjuvant Study: IPI-NIVO vs NIVO-RELA, *Janice Mehnert*

10.00 AM	Survivorship, <i>Tessa Flores*</i>
10.15 AM	Toxicities management, <i>Douglas Johnson*</i>
10.30 AM	DISCUSSION
10.45 AM	Coffee break**
11.00 AM	Engineered TILs, <i>Olivier Michielin</i>
11.15 AM	Novel MAPK Inhibitor, <i>Roger Lo</i>
11.30 AM	Do we need New Staging?, <i>Jeffrey Gershenwald</i>
11.45 AM	Cell Therapy, <i>Marc S. Ernstoff</i>

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

12.35 AM	Spatial Biology: YES or NO, <i>Carlo Bifulco* VS Jerome Galon*</i>
1.00 PM	Screening for melanoma: Population vs High Risk only, <i>Laura Ferris* VS Susana Puig*</i>
1.25 PM	Quality of Life vs Efficacy, <i>Omid Hamid VS Paul Nathan</i>
1.50 PM	Putting it all together: Practical Considerations for Monday Clinic, <i>Igor Puzanov</i>
2.05 PM	Conclusion